Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome

Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome : a Multicentric, Retrospective Cohort

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02854046

Acronym

CalciWest

Enrollment

Registered

2016-08-03

Start date

2016-07-01

Completion date

2016-10-31

Last updated

2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Calciphylaxis

Keywords

calcific uremic arteriolopathy, case-control study, cohort study

Brief summary

Calciphylaxis, also called Calcific Uremic Arteriolopathy (CUA) is a lethal affection mostly affecting patient in end stage renal disease. The survival rate is described around 20 to 46% at one year. Clinical presentation is very painful skin lesions with ulceration mostly located on the trunk or thigh. Current knowledge about physiopathology, diagnostic practice and therapeutic is very limited. Actually there is no European study about calciphylaxis and risk factors, diagnostic practice and outcome factors.

Interventions

OTHERCalcific Uremic Arteriolopathy

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients ≥ 18 years with chronic renal failure with Glomerular Filtration Rate \< 30ml/min/1,73m² * diagnosis of calciphylaxis between 2006 and 2016 * living in the Regions of Bretagne, Pays de la Loire, Poitou-Charentes or Centre Val de Loire.

Exclusion criteria

* realized biopsy in favor of differential diagnosis * significant arterial lesion of lesion area or differential diagnosis more valid * if the diagnosis is not based on the following criteria: 3 clinical criteria or 2 clinical criteria and biopsy in favor, criteria which are : * Patient in chronic hemodialysis or stade 4 chronic kidney disease * At least 2 painful sores and hardly curable with concomitant painful purpura * Sore and purpura localisation in trunk, extremities and penis.

Design outcomes

Primary

Measure	Time frame
Description of calcific uremic arteriolopathy in a French population by describing the characteristics of the population, diagnostic and treatment practices and patient outcome.	Up to 16 months

Secondary

Measure	Time frame
Study factors determining the patient outcome with calciphylaxis	Up to 16 months
Study case control of risk factors in the subgroup of patients in extra renal replacement therapy	Up to 16 months

Countries

France

Contacts

PRINCIPAL_INVESTIGATORMaryvonne HOURMANT, PHD

Nantes University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 25, 2026